finanzen.net
23.04.2019 02:00
Bewerten
(0)

Valid Insight Wins the Queen's Most Coveted Award for Enterprise

DRUCKEN

LONDON, April 22, 2019 /PRNewswire/ -- The Queen's Awards for Enterprise are the UK's most esteemed business awards, presented only to the most eminent of companies or individuals, demonstrating outstanding results in their field.

Today, Her Majesty the Queen announced approval of the Prime Minister's recommendation for Valid Insight to be honoured in recognition of the outstanding success of the company's growth strategy.

Valid Insight provides expert consultancy services that guide clients in the pharmaceutical, biotech and medical device industry to global market access success. Since being established in 2016, the company has grown exponentially, with their international client base and sales expanding by almost 800% in the last three years. In this time, they've also become a major brand in the market and are used by leading pharmaceutical companies worldwide.

The Queen's Awards for Enterprise are given to businesses that have excelled and achieved significant growth and commercial success over three years. The recognition for Valid Insight follows their work with client firms across Europe, Switzerland, USA and Japan involved in the development and commercialisation of medical treatments, diagnostics and devices across multiple therapy areas.

In recognition of the honour, Valid Insight's founder and Managing Director, Steve Bradshaw, has been invited to a Royal Reception at Buckingham Palace in June hosted by HRH The Prince of Wales.

Steve said, "We are honoured to receive the Queen's Award for Enterprise in International Trade. We compete against a strong set of consultancy firms on a global level and to win this award means that what we are doing is world class".

As a field-based enterprise, Valid Insight is free from any geographical limitations that restrict some of its competitors. They benefit from being able to select the best staff to provide local support, in their global operation. On top of this, services are supported by world-leading experts with decades of market access, medical and commercial experience.

Steve explains, "From the outset, our strategy was to create a competitive, truly differentiated, global strategy consulting firm with a virtual working model to attract the best talent irrespective of geography.

"We provide world-class expertise and strategic consulting solutions and tools to give the highest level of certainty around our clients' most critical business decisions, wherever they are based".

Valid Insight's global network of opinion leaders, payers and expert consultants provides the pharmaceutical and life sciences industry with strategic insight and tools to assist with difficult decision making, in often complex and uncertain marketplaces. The team at Valid Insight has extensive experience in helping companies commercialise their medicinal products in all key global markets and is renowned by top pharmaceutical clients for their hands-on, senior-led, pragmatic approach that produces concrete results throughout the entire life cycle of medical product development and commercialisation.

"Our flexible approach has achieved trusted partner status and repeat business with many top pharmaceutical, biotech and medical device companies worldwide. Our success is testament to the strength of our culture and the quality of our people and their commitment to fostering strong client relationships. I would like to thank our team for all their help in our recent achievements."

Focus is firmly on the future at Valid Insight, as they continuously strive towards consolidation and growth of client relationships, optimum results and continuous innovation. To this, they have developed industry-leading technology, including an innovative digital platform that allows companies to understand the market access and price potential of a product, plus determine the focus of product development to bring optimal value at launch at very early stages of development before heavy investment is made.

Reflecting on the significance of the award, Steve said, "To win the Queen's Award strengthens our reputation as a leader in the field and we look forward to an exciting future.

"Valid Insight continues to penetrate new global markets and is achieving ongoing success, and we continue to innovate to best serve our clients.

"This award will further encourage us to extend our high standard of expertise in the challenging area of pharmaceutical market access, helping more multinational companies bring better medicines to patients across the world".

About Valid Insight:  Valid Insight is an award-winning pharmaceutical global market access consultancy.

With a team that includes some of the world's leading market access and pricing experts, clients across the globe turn to us for innovative pricing, market access and value communication strategies through the full product development cycle. 

Proud winners of the Queen's Award for Enterprise: International Trade, we aim to offer world-class solutions that continue to drive growth for our global clients.

Valid Insight
Phone: +44 (0) 20 3750 9833
Email: discover@validinsight.com 
www.validinsight.com

Related Images

valid-insight-queens-award-for.png

Cision View original content:http://www.prnewswire.com/news-releases/valid-insight-wins-the-queens-most-coveted-award-for-enterprise-300835437.html

SOURCE Valid Insight

Nachhaltig investieren

Mit nachhaltigen Produkten investieren Sie in eine bessere Welt - ohne Abstriche bei der Rendite. Wie das gelingt, erklärt Heiko Geiger von der Bank Vontobel im Webinar um 18 Uhr.
Jetzt kostenlos anmelden!
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX fester -- Offenbar Millionenklage gegen VW in Saudi Arabien -- Fiat Chrysler schlägt Fusion mit Renault vor - Angriff auf VW -- Uniper, Schaeffler, LEONI im Fokus

Novartis: USA lassen mehr als zwei Millionen Dollar teures Medikament zu. Brexit-Partei stärkste Kraft bei Europawahl in GB. Nasdaq zieht Übernahmeangebot für Osloer Börse zurück. Deutsche Bank muss Trump-Unterlagen nicht sofort aushändigen. QIAGEN: PIK3CA-Biomarker-Test erhält FDA-Zulassung.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Apps & Social Media: Die wertvollsten Marken der Welt
Welche Marke macht das Rennen?
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
mehr Top Rankings

Umfrage

Die traditionellen Volksparteien haben bei den EU-Wahlen schwach abgeschnitten. Erwarten sie nun einen veränderten politischen Kurs Europas?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
NEL ASAA0B733
TeslaA1CX3T
Apple Inc.865985
Amazon906866
CommerzbankCBK100
BayerBAY001
BASFBASF11
Scout24 AGA12DM8
Allianz840400
BMW AG519000
Infineon AG623100
Volkswagen (VW) AG Vz.766403